CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.4319
+0.0219 (5.34%)
May 14, 2025, 11:43 AM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
510.85M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
CytoDyn News
- 20 hours ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 1 day ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire
- 8 days ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha
- 8 days ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - Benzinga
- 8 days ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - GlobeNewsWire
- 15 days ago - CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany - GlobeNewsWire
- 2 months ago - March 2025 Letter to Shareholders - GlobeNewsWire
- 2 months ago - CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - GlobeNewsWire